Enanta Pharmaceuticals Company Profile (NASDAQ:ENTA)

About Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals logoEnanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ENTA
  • CUSIP: N/A
  • Web: www.enanta.com
Capitalization:
  • Market Cap: $574.97 million
  • Outstanding Shares: 19,083,000
Average Prices:
  • 50 Day Moving Avg: $31.38
  • 200 Day Moving Avg: $31.28
  • 52 Week Range: $20.79 - $37.31
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 753.25
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $46.2 million
  • Price / Sales: 12.45
  • Book Value: $13.96 per share
  • Price / Book: 2.16
Profitability:
  • EBIDTA: ($18,830,000.00)
  • Net Margins: -18.92%
  • Return on Equity: -3.54%
  • Return on Assets: -3.38%
Debt:
  • Current Ratio: 34.85%
  • Quick Ratio: 34.85%
Misc:
  • Average Volume: 179,073 shs.
  • Beta: 0.81
  • Short Ratio: 7.35
 

Frequently Asked Questions for Enanta Pharmaceuticals (NASDAQ:ENTA)

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) posted its quarterly earnings results on Monday, May, 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.10. The firm earned $9 million during the quarter, compared to analyst estimates of $9.19 million. Enanta Pharmaceuticals had a negative return on equity of 3.54% and a negative net margin of 18.92%. Enanta Pharmaceuticals's quarterly revenue was down 30.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.09) EPS. View Enanta Pharmaceuticals' Earnings History.

Where is Enanta Pharmaceuticals' stock going? Where will Enanta Pharmaceuticals' stock price be in 2017?

2 equities research analysts have issued 1 year price objectives for Enanta Pharmaceuticals' stock. Their predictions range from $26.00 to $27.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $26.50 in the next twelve months. View Analyst Ratings for Enanta Pharmaceuticals.

What are analysts saying about Enanta Pharmaceuticals stock?

Here are some recent quotes from research analysts about Enanta Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. " (5/12/2017)
  • 2. JPMorgan Chase & Co. analysts commented, "Today after market close, Enanta reported F3Q financial results and provided a pipeline update. While we expect AbbVie’s Viekira Pak to remain a key driver for ENTA shares in 2016, we see the company’s wholly owned assets becoming increasingly important valuation drivers over time." (8/9/2016)

Who are some of Enanta Pharmaceuticals' key competitors?

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the folowing people:

  • Bruce L.A. Carter Ph.D., Chairman of the Board,Independent Director
  • Jay R. Luly Ph.D., President, Chief Executive Officer, Director
  • Paul J. Mellett Jr., Chief Financial Officer, Senior Vice President - Finance & Administration
  • Yat Sun Sun Or Ph.D., Senior Vice President - Research & Development, Chief Scientific Officer
  • Nathaniel S. Gardiner J.D., Senior Vice President, General Counsel
  • Nathalie Adda M.D., Senior Vice President and Chief Medical Officer
  • Timothy D. Ocain Ph.D., Senior Vice President - New Product Strategy and Development
  • Ernst-Gunter Afting M.D., Ph.D.,, Independent Director
  • Stephen Buckley Jr., Independent Director
  • George S. Golumbeski Ph.D., Independent Director

Who owns Enanta Pharmaceuticals stock?

Enanta Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.16%), State Street Corp (3.93%), Renaissance Technologies LLC (2.98%), Dimensional Fund Advisors LP (2.17%), Candriam Luxembourg S.C.A. (1.87%) and FMR LLC (1.51%). Company insiders that own Enanta Pharmaceuticals stock include Nathaniel S Gardiner, Paul J Mellett, Terry Vance and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

Who sold Enanta Pharmaceuticals stock? Who is selling Enanta Pharmaceuticals stock?

Enanta Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Acadian Asset Management LLC, Granahan Investment Management Inc. MA, FMR LLC, Alliancebernstein L.P., Stonepine Capital Management LLC, Spark Investment Management LLC and JPMorgan Chase & Co.. View Insider Buying and Selling for Enanta Pharmaceuticals.

Who bought Enanta Pharmaceuticals stock? Who is buying Enanta Pharmaceuticals stock?

Enanta Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, State Street Corp, Candriam Luxembourg S.C.A., Point72 Asset Management L.P., Vanguard Group Inc., Virginia Retirement Systems ET AL, Bank of America Corp DE and Prudential Financial Inc.. Company insiders that have bought Enanta Pharmaceuticals stock in the last two years include Nathaniel S Gardiner and Terry Vance. View Insider Buying and Selling for Enanta Pharmaceuticals.

How do I buy Enanta Pharmaceuticals stock?

Shares of Enanta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of Enanta Pharmaceuticals stock can currently be purchased for approximately $30.13.


MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)
Community Ranking:  2.1 out of 5 ( )
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  168
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Enanta Pharmaceuticals (NASDAQ:ENTA) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.50 (12.05% downside)

Analysts' Ratings History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/22/2016Robert W. BairdReiterated RatingOutperform$22.00 -> $27.00N/AView Rating Details
8/9/2016JPMorgan Chase & Co.Set Price TargetBuy$31.00 -> $26.00N/AView Rating Details
4/28/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
2/9/2016Barclays PLCBoost Price TargetUnderweight$16.00 -> $18.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Earnings by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)
Earnings History by Quarter for Enanta Pharmaceuticals (NASDAQ ENTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q2 2017($0.38)($0.28)$9.19 million$9.00 millionViewListenView Earnings Details
2/8/2017Q117($0.18)($0.26)$12.70 million$11.90 millionViewListenView Earnings Details
11/21/2016Q416($0.11)($0.09)$13.56 million$12.80 millionViewListenView Earnings Details
8/8/2016Q216($0.09)($0.06)$13.07 million$14.00 millionViewListenView Earnings Details
5/9/2016Q2$0.10($0.09)$16.80 million$13.00 millionViewListenView Earnings Details
2/8/2016Q116$1.13$1.36$47.32 million$48.40 millionViewListenView Earnings Details
11/23/2015Q415$0.15$0.29$16.44 million$14.40 millionViewListenView Earnings Details
8/6/2015Q315$0.19$0.13$16.18 million$11.60 millionViewListenView Earnings Details
5/7/2015Q215$1.80$1.49$63.40 million$57.40 millionViewListenView Earnings Details
2/5/2015Q115$3.82$2.18$86.62 million$77.50 millionViewN/AView Earnings Details
11/24/2014Q414($0.33)($0.27)$3.81 million$2.60 millionViewListenView Earnings Details
8/11/2014Q314$1.65$1.81$40.83 million$42.10 millionViewN/AView Earnings Details
5/12/2014Q2$0.69($0.28)$1.20 million$2.20 millionViewListenView Earnings Details
2/13/2014Q114($0.15)($0.30)$1.41 million$0.89 millionViewN/AView Earnings Details
11/25/2013Q4($0.29)($0.25)$1.00 million$1.30 millionViewListenView Earnings Details
8/12/2013Q213($0.34)($0.23)$0.73 million$1.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)
Current Year EPS Consensus Estimate: $-0.05 EPS
Next Year EPS Consensus Estimate: $0.04 EPS

Dividends

Dividend History for Enanta Pharmaceuticals (NASDAQ:ENTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Insider Ownership Percentage: 9.28%
Institutional Ownership Percentage: 71.61%
Insider Trades by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)
Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)
Insider Trades by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2017Yat Sun OrInsiderSell13,921$35.09$488,487.89View SEC Filing  
11/29/2016Yat Sun OrInsiderSell13,921$31.44$437,676.24View SEC Filing  
5/11/2016Nathaniel S GardinerVPBuy500$24.45$12,225.00View SEC Filing  
2/12/2016Terry VanceDirectorBuy2,000$27.04$54,080.00View SEC Filing  
11/24/2015Paul J. MellettCFOSell6,000$30.15$180,900.00View SEC Filing  
10/15/2015Paul J MellettCFOSell7,500$40.10$300,750.00View SEC Filing  
9/8/2015Paul J. MellettCFOSell7,500$39.55$296,625.00View SEC Filing  
7/13/2015Paul J MellettCFOSell7,500$46.29$347,175.00View SEC Filing  
7/13/2015Yat Sun OrInsiderSell3,750$46.29$173,587.50View SEC Filing  
6/11/2015Paul J MellettCFOSell7,500$42.51$318,825.00View SEC Filing  
6/11/2015Yat Sun OrInsiderSell3,750$42.47$159,262.50View SEC Filing  
6/5/2015Yat Sun OrInsiderSell10,750$42.02$451,715.00View SEC Filing  
5/19/2015Paul J MellettCFOSell24,000$40.13$963,120.00View SEC Filing  
5/11/2015Yat Sun OrInsiderSell8,000$36.13$289,040.00View SEC Filing  
3/9/2015Jay R LulyCEOSell15,000$33.37$500,550.00View SEC Filing  
2/20/2015Jay R LulyCEOSell15,000$35.35$530,250.00View SEC Filing  
2/19/2015Stephen Jr. BuckleyDirectorBuy1,000$34.00$34,000.00View SEC Filing  
2/17/2015Nathaniel S GardinerVPBuy1,400$33.23$46,522.00View SEC Filing  
1/16/2015Paul J MellettCFOSell4,500$49.45$222,525.00View SEC Filing  
1/5/2015Jay R LulyCEOSell15,000$50.43$756,450.00View SEC Filing  
12/1/2014Jay R LulyCEOSell15,000$45.39$680,850.00View SEC Filing  
11/3/2014Jay R LulyCEOSell15,000$42.52$637,800.00View SEC Filing  
9/15/2014Paul J MellettCFOSell10,000$39.83$398,300.00View SEC Filing  
8/14/2014Paul J MellettCFOSell10,000$39.13$391,300.00View SEC Filing  
8/14/2014Stephen Jr. BuckleyDirectorBuy1,000$38.95$38,950.00View SEC Filing  
7/14/2014Paul J MellettCFOSell20,000$39.88$797,600.00View SEC Filing  
5/1/2014Yat Sun OrInsiderSell5,000$36.98$184,900.00View SEC Filing  
4/1/2014Jay LulyCEOSell15,000$39.17$587,550.00View SEC Filing  
4/1/2014Yat Sun OrInsiderSell10,000$39.16$391,600.00View SEC Filing  
3/24/2014Yat Sun OrInsiderSell10,000$39.34$393,400.00View SEC Filing  
3/4/2014V Life Science Ventures Gm Tvmmajor shareholderSell439,334$38.82$17,054,945.88View SEC Filing  
2/26/2014V Life Science Ventures Gm Tvmmajor shareholderSell230,190$39.15$9,011,938.50View SEC Filing  
2/24/2014V Life Science Ventures Gm Tvmmajor shareholderSell60,477$39.57$2,393,074.89View SEC Filing  
2/14/2014Jay LulyCEOSell5,800$38.10$220,980.00View SEC Filing  
1/2/2014Jay R LulyCEOSell5,800$28.05$162,690.00View SEC Filing  
12/6/2013Marc E GoldbergDirectorSell6,861$27.93$191,627.73View SEC Filing  
10/14/2013Saints Capital Granite, L.P.Major ShareholderSell32,301$19.84$640,851.84View SEC Filing  
10/10/2013Saints Capital Granite, L.P.Major ShareholderSell36,207$21.71$786,053.97View SEC Filing  
10/3/2013Saints Capital Granite, L.P.Major ShareholderSell12,300$23.39$287,697.00View SEC Filing  
3/26/2013Helmut SchuhslerDirectorBuy132,949$14.00$1,861,286.00View SEC Filing  
3/26/2013Saints Capital Granite, L.P.Major ShareholderBuy66,474$14.00$930,636.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Enanta Pharmaceuticals (NASDAQ:ENTA)
Latest Headlines for Enanta Pharmaceuticals (NASDAQ:ENTA)
Source:
DateHeadline
americanbankingnews.com logoEnanta Pharmaceuticals Inc (ENTA) Expected to Post Quarterly Sales of $8.12 Million
www.americanbankingnews.com - May 26 at 1:48 PM
americanbankingnews.com logoZacks: Brokerages Expect Enanta Pharmaceuticals Inc (ENTA) to Announce -$0.49 Earnings Per Share
www.americanbankingnews.com - May 24 at 8:08 PM
americanbankingnews.com logoEnanta Pharmaceuticals Inc (ENTA) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - May 12 at 7:41 PM
finance.yahoo.com logoCORRECTING and REPLACING Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2017
finance.yahoo.com - May 9 at 8:41 PM
americanbankingnews.com logoEnanta Pharmaceuticals Inc (ENTA) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS
www.americanbankingnews.com - May 9 at 4:02 PM
finance.yahoo.com logoEdited Transcript of ENTA earnings conference call or presentation 8-May-17 8:30pm GMT
finance.yahoo.com - May 9 at 8:04 AM
baystreet.ca logoInvestor Network: Enanta Pharmaceuticals, Inc. to Host Earnings Call
www.baystreet.ca - May 8 at 4:50 PM
businesswire.com logoEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2017
www.businesswire.com - May 8 at 4:50 PM
marketbeat.com logoEnanta Pharmaceuticals reports 2Q loss
marketbeat.com - May 8 at 4:13 PM
americanbankingnews.com logoSomewhat Positive Media Coverage Very Likely to Impact Enanta Pharmaceuticals (ENTA) Share Price
www.americanbankingnews.com - May 4 at 7:58 PM
americanbankingnews.com logoEnanta Pharmaceuticals Inc (ENTA) Expected to Announce Quarterly Sales of $9.24 Million
www.americanbankingnews.com - May 3 at 1:09 PM
americanbankingnews.com logoZacks: Analysts Expect Enanta Pharmaceuticals Inc (ENTA) Will Announce Earnings of -$0.38 Per Share
www.americanbankingnews.com - May 1 at 9:02 PM
americanbankingnews.com logoFavorable News Coverage Very Likely to Impact Enanta Pharmaceuticals (ENTA) Stock Price
www.americanbankingnews.com - April 27 at 9:30 PM
americanbankingnews.com logoVery Positive Media Coverage Extremely Likely to Affect Enanta Pharmaceuticals (ENTA) Share Price
www.americanbankingnews.com - April 23 at 8:00 AM
businesswire.com logoEnanta Announces Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic, Ribavirin-Free HCV Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates ...
www.businesswire.com - April 21 at 11:59 AM
finance.yahoo.com logoEnanta Announces Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic, Ribavirin-Free HCV Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates in Challenging-to-Treat Genotype 3 Chronic HCV Patients
finance.yahoo.com - April 21 at 11:59 AM
finance.yahoo.com logoEnanta Announces 99 Percent SVR12 Rate in Chronic HCV Patients with Compensated Cirrhosis Treated with …
finance.yahoo.com - April 20 at 5:06 PM
finance.yahoo.com logoAbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis
finance.yahoo.com - April 20 at 12:30 PM
finance.yahoo.com logoEnanta Announces 99 Percent SVR12 Rate in Chronic HCV Patients with Compensated Cirrhosis Treated with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P)
finance.yahoo.com - April 20 at 12:30 PM
streetinsider.com logoEnanta Pharma (ENTA) Reports New Preclinical Data on EDP-305 for NASH and PBC at ILC
www.streetinsider.com - April 19 at 4:57 PM
finance.yahoo.com logoEnanta Announces New Preclinical Data on its FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC) at The International Liver Congress™ 2017
finance.yahoo.com - April 19 at 12:17 PM
finance.yahoo.com logoEnanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2017
finance.yahoo.com - April 18 at 4:41 PM
americanbankingnews.com logoEnanta Pharmaceuticals (ENTA) Receives Daily News Sentiment Score of 0.14
www.americanbankingnews.com - April 16 at 10:17 AM
americanbankingnews.com logo Brokerages Anticipate Enanta Pharmaceuticals Inc (ENTA) Will Announce Earnings of -$0.38 Per Share
www.americanbankingnews.com - April 10 at 2:30 PM
streetinsider.com logoEnanta Pharma (ENTA) Announces Data Presentations at ILC - StreetInsider.com
www.streetinsider.com - April 7 at 9:38 AM
finance.yahoo.com logoEnanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2017
finance.yahoo.com - April 7 at 9:38 AM
finance.yahoo.com logoEnanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ENTA-US : April 6, 2017
finance.yahoo.com - April 7 at 9:38 AM
businesswire.com logoEnanta Pharmaceuticals to Present at the H.C. Wainwright 1st ... - Business Wire (press release)
www.businesswire.com - March 28 at 4:42 PM
finance.yahoo.com logoEnanta Pharmaceuticals to Present at the H.C. Wainwright 1st Annual NASH Investor Conference
finance.yahoo.com - March 27 at 4:46 PM
streetinsider.com logoEnanta Pharma (ENTA) Announces Japanese MHLW Grants Priority Review for AbbVie's Investigational HCV ... - StreetInsider.com
www.streetinsider.com - March 16 at 11:20 PM
streetinsider.com logoEnanta Pharma (ENTA) Announces Japanese MHLW Grants Priority Review for AbbVie's Investigational HCV Regimen of G/P for Treatment
www.streetinsider.com - March 14 at 9:24 PM
businesswire.com logoEnanta Announces Japanese Ministry of Health, Labour and Welfare Grants Priority Review for AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the ...
www.businesswire.com - March 14 at 12:51 PM
finance.yahoo.com logoEnanta Announces Japanese Ministry of Health, Labour and Welfare Grants Priority Review for AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
au.finance.yahoo.com - March 14 at 12:51 PM
seekingalpha.com logoEnanta: Half Cash, All Upside - Seeking Alpha
seekingalpha.com - February 28 at 5:09 PM
streetinsider.com logoEnanta Pharma (ENTA) Announces CHMP Grants Positive Opinion for 8-Week Treatment Option with AbbVie's ... - StreetInsider.com
www.streetinsider.com - February 28 at 8:23 AM
businesswire.com logoEnanta Announces CHMP Grants Positive Opinion for an Eight-Week Treatment Option with AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir ...
www.businesswire.com - February 27 at 7:26 PM
us.rd.yahoo.com logoEnanta Announces CHMP Grants Positive Opinion for an Eight-Week Treatment Option with AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C
us.rd.yahoo.com - February 27 at 7:26 PM
us.rd.yahoo.com logo6:03 am Enanta Pharmaceuticals confirms that the CHMP of the EMA has granted a positive opinion for an eight-week treatment regimen of AbbVie's VIEKIRAX
us.rd.yahoo.com - February 27 at 7:26 PM
biz.yahoo.com logoENANTA PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - February 22 at 8:04 AM
finance.yahoo.com logoENANTA PHARMACEUTICALS INC Financials
finance.yahoo.com - February 16 at 4:28 PM
biz.yahoo.com logoENANTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - February 9 at 5:35 PM
biz.yahoo.com logoQ1 2017 Enanta Pharmaceuticals Inc Earnings Release - After Market Close
us.rd.yahoo.com - February 8 at 5:30 PM
us.rd.yahoo.com logoEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2016
us.rd.yahoo.com - February 8 at 5:30 PM
biz.yahoo.com logoENANTA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
us.rd.yahoo.com - February 8 at 5:30 PM
biz.yahoo.com logoEnanta Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
us.rd.yahoo.com - February 8 at 5:30 PM
finance.yahoo.com logoEnanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
finance.yahoo.com - February 6 at 5:02 PM
businesswire.com logoEnanta Announces U.S. FDA Grants Priority Review to AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All ...
www.businesswire.com - February 2 at 5:29 PM
us.rd.yahoo.com logoEnanta Announces U.S. FDA Grants Priority Review to AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
us.rd.yahoo.com - February 2 at 5:29 PM
businesswire.com logoEnanta Announces EMA Grants Accelerated Assessment, Validates Marketing Authorization Application for AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P ...
www.businesswire.com - January 24 at 10:42 PM
benzinga.com logoEnanta Announces EMA Grants Accelerated...
www.benzinga.com - January 24 at 5:40 PM

Social

Chart

Enanta Pharmaceuticals (ENTA) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff